Although the role of EZH2 is context dependent, a substantial amount of the literature on preclinical models suggests that targeting EZH2 in combination with cisplatin chemotherapy could have beneficial effects in the treatment of lung, ovarian, and breast cancers. The gene discussed is EZH2; the disease is breast cancer.